OKYO Pharma Announces Successful Type C Meeting with the FDA
MWN-AI** Summary
OKYO Pharma Limited (Nasdaq: OKYO), a biopharmaceutical company focused on treating neuropathic corneal pain (NCP) and inflammatory eye diseases, announced a successful Type C meeting with the FDA concerning the Phase 2b/3 clinical trial of its investigational therapy, urcosimod. The meeting yielded several positive confirmations from the FDA, notably the acceptance of a primary endpoint based on a 2-point improvement on the Visual Analogue Scale (VAS) for pain reduction at the 12-week mark, which the agency considers clinically meaningful.
Additionally, the FDA provided statistical guidance aimed at strengthening the robustness of the clinical data, suggesting that if the statistical analysis plan is completed prior to unmasking and the results are favorable, this could support efficacy determinations at a future End-of-Phase meeting. The FDA also endorsed OKYO’s study design, sample size, and powering assumptions, indicating that the Ocular Pain Assessment Survey would serve as suitable quality-of-life data.
Raj Patil, Chief Scientific Officer at OKYO, expressed satisfaction with the progress made towards aligning the clinical development program with FDA expectations, emphasizing its importance in meeting a critical medical need for NCP patients. CEO Robert Dempsey praised the efforts of the OKYO team, noting that this successful meeting marks a significant inflection point for urcosimod and underscores the importance of continued efforts to innovate in treating this debilitating condition.
Urcosimod has previously shown promise in reducing pain in both dry eye disease and NCP models. With the first 120-patient Phase 2b/3 study set to commence in the first half of 2026, OKYO aims to address the gap in effective treatments for NCP, a condition that currently has no FDA-approved therapies.
MWN-AI** Analysis
The recent announcement from OKYO Pharma Limited (Nasdaq: OKYO) regarding a successful Type C meeting with the FDA marks a significant advancement for the company, particularly in the development of its investigational therapy, urcosimod, for the treatment of neuropathic corneal pain (NCP). This development highlights several key factors that investors should consider when evaluating OKYO's market potential.
Firstly, the FDA's endorsement of the proposed primary endpoint, along with their agreement on the study design and statistical methodology, decreases regulatory uncertainty substantially. Given that urcosimod successfully demonstrated statistical significance in prior trials, this received endorsement can be seen as a strong validation of its therapeutic potential. Such regulatory clarity enhances the likelihood of successful progression into pivotal trials and market entry, which could drive the stock price positively.
Moreover, the company occupies a unique niche with no current FDA-approved therapies for NCP, suggesting a promising market opportunity for urcosimod. The acknowledgment of a significant unmet medical need and potential commercial viability can attract interest from institutional investors and analysts, thereby increasing liquidity in the stock.
Investors should also monitor the upcoming Phase 2b/3 clinical trial initiation slated for the first half of 2026. Positive trial results can catalyze stock momentum, as evidenced by the biotech sector's typical trading patterns around pivotal trial announcements. However, while optimism is warranted, investors must remain cautious given inherent clinical trial risks and stock volatility associated with biotech companies.
In summary, as OKYO Pharma moves toward its next clinical milestone, the firm is positioned for potential upside, but investors should stay attuned to clinical outcomes and regulatory developments, as these will significantly influence stock performance in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that it held a successful Type C meeting with the Food & Drug Administration (FDA) regarding the Phase 2b/3 human clinical trial of urcosimod for the treatment of neuropathic corneal pain (NCP).
Key highlights from the Type C FDA meeting include:
- FDA confirms the approach that the proposed primary endpoint of the Visual Analogue Scale (VAS) pain reduction at Week 12 is clinically meaningful, including explicit acknowledgment that a ?2-point improvement on the VAS scale represents a meaningful treatment effect
- The Agency provided statistical guidance to enhance robustness, noting that if the statistical analysis plan (SAP) is finalized prior to unmasking and results are strong, the data could provide substantial evidence of effectiveness at a future End-of-Phase 2b/3 meeting
- FDA endorsed the proposed study design, sample size, and powering assumptions, and agreed that the Ocular Pain Assessment Survey (OPAS) is appropriate as supportive quality-of-life evidence
- FDA alignment on the Chemistry, Manufacturing and Controls (CMC) strategy and key clinical elements, with no material issues raised, derisking the pathway to a pivotal trial and supports potential registration if study results are robust
“We were very pleased to achieve meaningful progress with the FDA toward alignment on urcosimod’s clinical development program,” said Raj Patil, Ph.D., Chief Scientific Officer at OKYO Pharma. “This alignment represents an important step forward and underscores the potential to address a significant unmet medical need in patients with neuropathic corneal pain.”
“I want to thank the entire OKYO team for their focus, rigor, and collaboration that led to this successful Type C meeting with the FDA,” said Robert Dempsey, CEO of OKYO Pharma. “This positive outcome reflects years of disciplined scientific and clinical execution; moreover, the FDA’s alignment on our Phase 2b/3 strategy meaningfully de-risks the program. The results of this meeting also represent a meaningful value-inflection point for urcosimod and, most importantly, a step forward for patients suffering from neuropathic corneal pain, where the unmet need remains profound.”
As previously communicated, urcosimod was granted the first IND to treat patients with NCP and was awarded fast track designation by the Food and Drug Administration (FDA). The company expects to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
About Neuropathic Corneal Pain (NCP)
Neuropathic corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of corneal sensory nerves, often in combination with inflammatory processes, and may occur in patients with a range of underlying ophthalmic conditions. There are currently no FDA-approved therapies specifically for NCP, resulting in patients being treated with limited or no success using various topical and systemic medications in an off-label manner.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Urcosimod showed clear statistical significance in multiple endpoints in an earlier 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2025. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com
FAQ**
How does the recent Type C meeting with the FDA impact OKYO Pharma Limited OKYO's strategy for its clinical trials in London and New York?
In what ways is OKYO Pharma Limited OKYO planning to leverage its success with the FDA to attract potential investors in both London and New York markets?
How might the approval of urcosimod by the FDA influence the perception of OKYO Pharma Limited OKYO in the London and New York biotech investment community?
What are the potential implications for OKYO Pharma Limited OKYO's share price and market position in London and New York upon successful completion of its Phase 2b/3 trial?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
0.0% G/L:
$1.68 Last:
15,469 Volume:
$1.69 Open:
